Newly Diagnosed High Risk Neuroblastoma Clinical Trial
Official title:
Response-based Treatment of High-risk Neuroblastoma
The purpose of this study is to improve outcome of high risk neuroblastoma by tailoring the treatment intensity of tandem high dose chemotherapy according to the treatment response to induction chemotherapy.
Although the outcome of high-risk neuroblastoma improved after the introduction of high-dose
chemotherapy and autologous stem cell transplantation (HDCT/autoSCT), the outcome still
needs to be unsatisfactory.
In the investigator's previous study, good responders who had greater reduction of tumor
volume after induction chemotherapy showed lower relapse-free survival compared to poor
responders.Simultaneously, the reduction in tumor volume also was greater in patients who
died of treatment related mortality than patients who had relapsed tumors. These findings
suggest that tailoring treatment intensity according to the early tumor response to
induction chemotherapy may improve patient outcomes. So, in this study investigators
tailored the treatment intensity of high dose chemotherapy according to the treatment
response to induction chemotherapy.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment